Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29998620 | 0.85 | USP30 (0.33) | — | |
| SCHEMBL29999454 | 0.84 | EGFR (0.34) | — | |
| SCHEMBL21563581 | 0.83 | KRAS (0.31) | ACKR3 | |
| SCHEMBL29999075 | 0.80 | KRAS (0.45) | — | |
| SCHEMBL29999654 | 0.78 | KRAS (0.32) | — | |
| SCHEMBL29998717 | 0.75 | GSK3B (0.30) | — | |
| SCHEMBL21136745 | 0.75 | ACKR3 (0.31) | ACKR3 | |
| SCHEMBL29999675 | 0.73 | GRM5 (0.36) | — | |
| SCHEMBL21938013 | 0.71 | KRAS (0.49) | PIK3CD | |
| SCHEMBL29999753 | 0.70 | NOS3 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216762-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | OXA1L, GRIK4, GRIK5 | PIK3CD 1456/4885ACKR3 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.